Home › Companies › DAY ONE BIOPHARMACEUTICALS INC. › 2024-2025
Compiled from SEC Form N-PX filings and DAY ONE BIOPHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-03 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2024-2025
Explore DAY ONE BIOPHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are DAY ONE BIOPHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Natalie Holles | 81,975,302 | -- | -- | 1,357,027 | 6,470,934 | Majority: yes |
| Elect Director: Garry Nicholson, M.B.A. | 65,553,238 | -- | -- | 17,779,091 | 6,470,934 | Majority: yes |
| 2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. | 89,705,033 | 74,951 | 23,279 | -- | -- | Majority: yes |
| 3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. | 82,385,592 | 879,957 | 66,780 | -- | 6,470,934 | Majority: yes |
Source: DAY ONE BIOPHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-03 — read the filing on EDGAR.
Each item below shows how the 169 asset managers that disclosed a DAY ONE BIOPHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held 2025-06-02.
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.”): 82,385,592 for, 879,957 against, per its Form 8-K filed 2025-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,389,859 outstanding shares: 94% for, 1% against (95% of the company cast a for/against vote).
The 167 asset managers below cast 99.7% of the shares they voted on this item FOR (80,108,226 for, 208,803 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 22,848,777 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 6,430,257 | 0 | 0 | 0 | For |
| Vanguard | 5,986,332 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 4,913,327 | 0 | 0 | 0 | For |
| BlackRock | 4,114,911 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 3,935,683 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 3,348,466 | 0 | 0 | 0 | For |
| Estuary Capital Management LP | 3,318,406 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,753,557 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 2,113,323 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,885,025 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 1,865,684 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,736,748 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,529,920 | 0 | 0 | 0 | For |
| State Street | 1,157,697 | 0 | 0 | 0 | For |
| Charles Schwab | 1,055,985 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 862,068 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 761,363 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 662,197 | 0 | 0 | 0 | For |
| Dimensional | 621,493 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 430,814 | 0 | 0 | 0 | For |
| Northern Trust | 409,892 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 364,238 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 350,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 167 asset managers. See all 167 in the interactive database.
Meeting held 2025-06-02.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Garry Nicholson, M.B.A.”): 65,553,238 for, 17,779,091 withheld, per its Form 8-K filed 2025-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,389,859 outstanding shares: 75% for, 20% withheld (95% of the company cast a for/withheld vote).
The 53 asset managers below cast 100% of the shares they voted on this item FOR (22,866,484 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 379,585 | 0 | Abstain |
| State Street | 335 | 0 | 154,122 | 0 | Abstain |
| Equitable | 85,995 | 0 | 62,790 | 0 | For |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 110,000 | 0 | Abstain |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 0 | 77,906 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 76,829 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 67,343 | 0 | Abstain |
| SEI | 0 | 0 | 66,100 | 0 | Abstain |
| Exchange Place Advisors Trust | 0 | 0 | 49,857 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 40,345 | 0 | Abstain |
| ProShares | 0 | 0 | 38,925 | 0 | Abstain |
| Northern Trust | 0 | 0 | 32,325 | 0 | Abstain |
| Global X | 0 | 0 | 32,210 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 28,227 | 0 | Abstain |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Meeting held 2025-06-02.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Natalie Holles”): 81,975,302 for, 1,357,027 withheld, per its Form 8-K filed 2025-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,389,859 outstanding shares: 94% for, 2% withheld (95% of the company cast a for/withheld vote).
The 53 asset managers below cast 100% of the shares they voted on this item FOR (23,717,591 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 379,585 | 0 | Abstain |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 85,995 | 0 | 62,790 | 0 | For |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 73,329 | 0 | 3,500 | 0 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| Brighthouse | 20,948 | 0 | 19,397 | 0 | For |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Meeting held 2025-06-02.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”): 89,705,033 for, 74,951 against, per its Form 8-K filed 2025-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,389,859 outstanding shares: 100% for, 0.1% against (100% of the company cast a for/against vote).
The 53 asset managers below cast 100% of the shares they voted on this item FOR (24,190,909 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,729,592 | 0 | 0 | 0 | For |
| Vanguard | 5,825,813 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,334,142 | 0 | 0 | 0 | For |
| BlackRock | 2,169,498 | 0 | 0 | 0 | For |
| T. Rowe Price | 756,520 | 0 | 0 | 0 | For |
| Charles Schwab | 527,987 | 0 | 0 | 0 | For |
| Dimensional | 379,585 | 0 | 0 | 0 | For |
| State Street | 154,457 | 0 | 0 | 0 | For |
| Equitable | 148,785 | 0 | 0 | 0 | For |
| TIAA | 137,846 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 110,000 | 0 | 0 | 0 | For |
| Tema ETF Trust | 92,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,950 | 0 | 0 | 0 | For |
| WisdomTree | 77,906 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,829 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 67,343 | 0 | 0 | 0 | For |
| SEI | 66,100 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,857 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 40,751 | 0 | 0 | 0 | For |
| Brighthouse | 20,948 | 0 | 19,397 | 0 | For |
| ProShares | 38,925 | 0 | 0 | 0 | For |
| Northern Trust | 32,325 | 0 | 0 | 0 | For |
| Global X | 32,210 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,227 | 0 | 0 | 0 | For |
| JPMorgan | 24,836 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Meeting held 2024-05-23 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
DAY ONE BIOPHARMACEUTICALS INC.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.”): 73,212,768 for, 612,128 against, per its Form 8-K filed 2024-05-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 87,389,859 outstanding shares: 84% for, 0.8% against (84% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (260 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| COLDSTREAM CAPITAL MANAGEMENT INC | 260 | 0 | 0 | 0 | For |
| Echo45 Advisors LLC | 0 | 0 | 0 | 0 | -- |
Ranked by the number of DAY ONE BIOPHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 87,389,859 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 26.15% |
| 2 | Atlas Venture Life Science Advisors, LLC | 7.36% |
| 3 | Vanguard | 6.85% |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 5.62% |
| 5 | BlackRock | 4.71% |
| 6 | FRANKLIN ADVISERS INC | 4.50% |
| 7 | PICTET ASSET MANAGEMENT SA | 3.83% |
| 8 | Estuary Capital Management LP | 3.80% |
| 9 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.15% |
| 10 | FRANKLIN STRATEGIC SERIES | 2.67% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| AI Day 1 LLC | 15.74% | DEF14A |
| FMR (Fidelity) | 15.68% | 13F |
| Fidelity | 14.75% | DEF14A |
| BlackRock | 7.73% | 13F |
| Entities affiliated with Atlas Venture | 7.36% | DEF14A |
| Vanguard Group | 6.80% | 13F |
| RA Capital Management, L.P. | 6.59% | DEF14A |
| Glazer Capital, LLC | 6.43% | 13G |
| Franklin Templeton | 4.60% | 13F |
| Jeremy Bender, Ph.D., M.B.A. | 4.35% | DEF14A |
Percentages above are of 87,389,859 shares outstanding, as reported by DAY ONE BIOPHARMACEUTICALS INC. on its Form 10-Q dated 2024-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DAY ONE BIOPHARMACEUTICALS INC.’s 10-Q dated 2024-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At DAY ONE BIOPHARMACEUTICALS INC.'s shareholder meeting held 2025-06-02, in the 2024-2025 proxy season, 169 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 906 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: DAY ONE BIOPHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-03.
DAY ONE BIOPHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).